专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160368905A1 ANTIVIRAL COMPOUNDS AND USES THEREOF 有权
标题翻译：有害化合物及其用途
公开(公告)号：US20160368905A1
公开(公告)日：2016-12-22
申请号：US15141556
申请日：2016-04-28
申请人： AbbVie Inc.
发明人： David A. Betebenner , John K. Pratt , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Douglas K. Hutchinson , Warren M. Kati , Allan C. Krueger , Kenton L. Longenecker , Clarence J. Maring , John T. Randolph , Todd W. Rockway , Michael D. Tufano , Rolf Wagner , Dachun Liu
IPC分类号： C07D409/10 , A61K31/513 , C07D213/64 , A61K31/4418 , C07C311/08 , A61K31/18 , C07D233/72 , A61K31/4166 , A61K31/27 , C07D263/24 , A61K31/421 , C07D239/10 , C07D207/27 , A61K31/402 , C07D405/10 , C07D403/10 , A61K45/06 , A61K31/425 , C07D275/02 , C07D239/54
CPC分类号： C07D409/10 , A61K31/18 , A61K31/27 , A61K31/402 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/4418 , A61K31/503 , A61K31/513 , A61K45/06 , C07C311/08 , C07D207/27 , C07D213/64 , C07D233/32 , C07D233/72 , C07D239/10 , C07D239/54 , C07D263/22 , C07D263/24 , C07D275/02 , C07D403/10 , C07D405/10 , Y02P20/55
摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
摘要翻译：本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

2. 发明申请

US20090306045A1 Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease 审中-公开
标题翻译：抑制糖原合酶激酶和治疗自身免疫性或免疫性炎性疾病的方法
公开(公告)号：US20090306045A1
公开(公告)日：2009-12-10
申请号：US11991654
申请日：2006-12-22
申请人： Ira Mellman , Aimin Jiang
发明人： Ira Mellman , Aimin Jiang
IPC分类号： A61K31/55 , A61K31/4015 , A61P37/00
CPC分类号： A61K31/4745 , A61K31/503
摘要： The present invention relates to the use of glycogen synthase kinase 3(GSK3) inhibitors, especially inhibitors of GSK-3α, GSK-3β and GSK-3β2, preferably, inhibitors of GSK-3β, in patients having autoimmune diseases and/or immune dysfunction/dysregulation to induce immune tolerance. Inhibition of GSK leads to activation of a pathway of dendritic cell maturation which leads to a dendritic phenotype which attenuates, rather than induces, immune responses. The immune responses and mature dendritic cells produced by the method of the present invention redirect or attenuate the immune response in individuals, thus leading to effective therapies for a number of autoimmune diseases and/or diseases of immune dysfunction/dysregulation (immune inflammatory diseases), including systemic lupus erythematosus (SLE), autoimmune diabetes (type I diabetes mellitus), asthma, rheumatoid arthritis, inflammatory bowel disease, among numerous others.
摘要翻译：本发明涉及在具有自身免疫性疾病和/或免疫功能障碍的患者中使用糖原合酶激酶3（GSK3）抑制剂，特别是GSK-3α，GSK-3β和GSK-3β2抑制剂，优选GSK-3β抑制剂 /失调诱导免疫耐受。 GSK的抑制导致树突细胞成熟途径的激活，这导致树突状表型减弱而不是诱导免疫应答。通过本发明的方法产生的免疫应答和成熟树突状细胞改变或减弱个体的免疫应答，从而导致许多自身免疫疾病和/或免疫功能障碍/失调（免疫炎性疾病）疾病的有效治疗，包括系统性红斑狼疮（SLE），自身免疫性糖尿病（I型糖尿病），哮喘，类风湿性关节炎，炎性肠病等。

3. 发明授权

US07411064B2 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands 失效
标题翻译： 1-杂环烷基-3-磺酰基氮杂吲哚或吖草唑衍生物作为5-羟色胺-6配体
公开(公告)号：US07411064B2
公开(公告)日：2008-08-12
申请号：US11354459
申请日：2006-02-15
申请人： Ronald Charles Bernotas , Steven Edward Lenicek , Hassan Mahmoud Elokdah , David Zenan Li
发明人： Ronald Charles Bernotas , Steven Edward Lenicek , Hassan Mahmoud Elokdah , David Zenan Li
IPC分类号： C07D413/00 , A01N43/64 , A61K31/41
CPC分类号： C07D487/08 , A61K31/454 , A61K31/4745 , A61K31/498 , A61K31/503
摘要： The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor
摘要翻译：本发明提供式I化合物及其用于治疗与5-HT 6受体相关或受其影响的中枢神经系统疾病的用途

4. 发明授权

US07405300B2 Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) 失效
标题翻译：取代的吲哚作为聚（ADP-核糖）聚合酶（PARP）的抑制剂
公开(公告)号：US07405300B2
公开(公告)日：2008-07-29
申请号：US10933098
申请日：2004-09-01
申请人： John Z. Jiang , Jack Roger Koehl , Shujaath Mehdi , Neil David Moorcroft , Kwon Yon Musick , Philip Marvin Weintraub , Paul Robert Eastwood
发明人： John Z. Jiang , Jack Roger Koehl , Shujaath Mehdi , Neil David Moorcroft , Kwon Yon Musick , Philip Marvin Weintraub , Paul Robert Eastwood
IPC分类号： C07D403/04 , C07D209/04
CPC分类号： C04B35/632 , A61K31/404 , A61K31/454 , A61K31/4745 , A61K31/496 , A61K31/503 , A61K31/5377 , A61K31/541 , A61K31/55 , C07D209/40 , C07D401/04 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/10 , C07D405/12 , C07D405/14 , C07D409/04 , C07D471/04 , C07D487/08
摘要： The present invention relates to a series of substituted indole derivatives of the formula I: wherein R, R1, R2, R3, R4, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5′-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
摘要翻译：本发明涉及一系列式I的取代的吲哚衍生物：其中R 1，R 2，R 2，R 3，R 3， X和Y如本文所定义。本发明还涉及制备这些化合物的方法。本发明的化合物是聚（腺苷5'-二磷酸核糖）聚合酶（PARP）的抑制剂，因此可用作药剂，特别是用于治疗和/或预防各种疾病，包括与中枢神经相关的疾病系统和心血管疾病。

5. 发明授权

US07320989B2 Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists 失效
公开(公告)号：US07320989B2
公开(公告)日：2008-01-22
申请号：US10924181
申请日：2004-08-23
申请人： Eric Anderson , Brian Dupre , Daxin Gao , Raymond J. Kessler , Wen Li , Chengde Wu
发明人： Eric Anderson , Brian Dupre , Daxin Gao , Raymond J. Kessler , Wen Li , Chengde Wu
IPC分类号： A61K31/44 , C07D215/38 , C07D211/72
CPC分类号： A61K31/503 , A61K31/513 , A61K31/5377 , C07D413/14
摘要： The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.

6. 发明申请

US20070264485A1 AEROGEL-BASED ENCLOSURE SYSTEMS 审中-公开
标题翻译：基于AIRGEL的外壳系统
公开(公告)号：US20070264485A1
公开(公告)日：2007-11-15
申请号：US11748914
申请日：2007-05-15
申请人： Christopher J. Stepanian , Shahrooz Zaghi
发明人： Christopher J. Stepanian , Shahrooz Zaghi
IPC分类号： B05D7/00 , B32B3/26
CPC分类号： A61K31/195 , A61K31/385 , A61K31/4745 , A61K31/496 , A61K31/498 , A61K31/503 , Y10T428/249953
摘要： Enclosures of several type useful in transportation or thermally sensitive materials comprising a fiber reinforced aerogel material is described. Enclosures may take several forms and the aerogel material may be encapsulated with polymeric materials. Various methods of manufacturing such enclosures are also described.
摘要翻译：描述了可用于包含纤维增强气凝胶材料的运输或热敏材料中的几种类型的外壳。外壳可能采取几种形式，并且气凝胶材料可以用聚合物材料包封。还描述了制造这种外壳的各种方法。

7. 发明申请

US20060148807A1 Pyrrolo[1,2b]pyridazine compounds and their uses 审中-公开
标题翻译：吡咯并[1,2b]哒嗪化合物及其用途
公开(公告)号：US20060148807A1
公开(公告)日：2006-07-06
申请号：US11378537
申请日：2006-03-17
申请人： Jian-min Fu
发明人： Jian-min Fu
IPC分类号： A61K31/503 , G01N33/53
CPC分类号： A61K31/503 , G01N33/566 , G01N2500/00
摘要： Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I): including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R is H or Me.
摘要翻译：公开了新的CRF受体拮抗剂及其用于治疗多种疾病的用途，包括表现出CRF过度分泌或与CRF或CRF受体如焦虑和抑郁症相关的疾病。本发明的CRF受体拮抗剂具有式（I）的结构：包括立体异构体或立体异构体的混合物，药学上可接受的前药或其药学上可接受的盐，其中在式（I）中R是H或Me。

8. 发明申请

US20060128655A1 Use of hyaluronic acid or its derivatives to enhance delivery of antineoplastic agents 审中-公开
标题翻译：使用透明质酸或其衍生物来增强抗肿瘤剂的输送
公开(公告)号：US20060128655A1
公开(公告)日：2006-06-15
申请号：US11245816
申请日：2005-10-07
申请人： Rudolf Falk , Samuel Asculai
发明人： Rudolf Falk , Samuel Asculai
IPC分类号： A61K31/728 , A61K31/60 , A61K31/405 , A61K31/192
CPC分类号： A61K9/0019 , A61K9/0014 , A61K31/10 , A61K31/13 , A61K31/19 , A61K31/192 , A61K31/195 , A61K31/196 , A61K31/375 , A61K31/40 , A61K31/405 , A61K31/407 , A61K31/44 , A61K31/503 , A61K31/54 , A61K31/5415 , A61K31/616 , A61K31/715 , A61K31/728 , A61K45/06 , A61K47/36 , A61K47/61 , Y10S514/886 , Y10S514/887 , A61K2300/00
摘要： A combination for administration to a mammal which combination employs a therapeutically effective amount of a medicinal and/or therapeutic agent to treat a disease or condition and an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments and subunits of hyaluronic acid sufficient to facilitate the agent's penetration through the tissue (including scar tissue) at the site to be treated, through the cell membranes into the individual cells to be treated.
摘要翻译：用于给予哺乳动物的组合，其组合使用治疗有效量的药物和/或治疗剂来治疗疾病或病症以及一定量的透明质酸和/或其盐和/或同系物，类似物，衍生物，复合物，透明质酸的酯，片段和亚单元，其足以促进试剂穿过待处理部位的组织（包括瘢痕组织）穿过细胞膜进入待治疗的个体细胞。

9. 发明授权

US06730675B2 Compounds and methods for the treatment of pain 失效
标题翻译：用于治疗疼痛的化合物和方法
公开(公告)号：US06730675B2
公开(公告)日：2004-05-04
申请号：US10168762
申请日：2003-02-12
申请人： Megan Murphy , Rebecca Ann Urbanek , Wenhua Xiao , Gary Banks Steelman , Dean Gordon Brown , Thomas Michael Bare
发明人： Megan Murphy , Rebecca Ann Urbanek , Wenhua Xiao , Gary Banks Steelman , Dean Gordon Brown , Thomas Michael Bare
IPC分类号： C07D47104
CPC分类号： C07D471/04 , A61K31/5025 , A61K31/503 , A61K31/5377 , A61K31/541 , C07D487/04
摘要： Compounds according to structural diagram I are disclosed; wherein R1, A and D are as defined in the specification. Also disclosed are methods for treating pain comprising administration of a pain-ameliorating effective amount of a compound in accord with structural diagram I and pharmaceutical compositions comprising a pain-ameliorating effective amount of a compound in accord with structural diagram I.
摘要翻译：公开了根据结构图I的化合物;其中R 1，A和D如说明书中所定义。还公开了治疗疼痛的方法，其包括根据结构图I施用改善疼痛的有效量的化合物，以及根据结构图I包含疼痛改善的有效量的化合物的药物组合物。

10. 发明申请

US20040023970A1 1-Heterocyclylalkyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands 失效
标题翻译： 1-杂环烷基-3-磺酰基氮杂吲哚或吖草唑衍生物作为5-羟色胺-6配体
公开(公告)号：US20040023970A1
公开(公告)日：2004-02-05
申请号：US10621432
申请日：2003-07-17
申请人： Wyeth
发明人： Ronald Charles Bernotas , Steven Edward Lenicek , Hassan Mahmoud Elokdah , David Zenan Li
IPC分类号： A61K031/519 , A61K031/503 , A61K031/498 , A61K031/4745 , C07D471/02 , C07D487/02
CPC分类号： C07D487/08 , A61K31/454 , A61K31/4745 , A61K31/498 , A61K31/503
摘要： The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. 1
摘要翻译：本发明提供式I化合物及其用于治疗与5-HT 6受体相关或受其影响的中枢神经系统疾病的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式